Last updated: June 22, 2026
Aurobindo Pharma Ltd. v. Azurity Pharmaceuticals Inc., case number 1:26-cv-00265, is a federal patent dispute filed in 2026. No public case record details (asserted patents, filing date, venue, claim construction posture, motions, or asserted Orange Book triggers) are available in the provided input, so a litigation summary tied to specific patents, asserted claims, or current procedural status cannot be produced without fabricating facts.
What is the case background for Aurobindo Pharma Ltd. v. Azurity Pharmaceuticals Inc. 1:26-cv-00265?
Answer: Insufficient information to summarize case background accurately.
Case identifiers and what they imply for patent litigation timing
Aurobindo’s and Azurity’s roles in US patent litigation typically track FDA exclusivity and Orange Book listing exposure, but the specific drug, Orange Book listing, and patent numbers for 1:26-cv-00265 are not provided, so the timeline cannot be anchored to regulatory milestones.
Court, jurisdiction, and docket scope
The docket number alone does not establish whether this is a Hatch-Waxman infringement action under 35 U.S.C. § 271(e)(2), a declaratory judgment dispute, or a broader IP case. Without the complaint caption details (drug name and patents), docket scope cannot be mapped.
What patents are asserted in Aurobindo Pharma v. Azurity 1:26-cv-00265?
Answer: Not specified in the provided information.
How asserted patents usually map to Orange Book entries
For Hatch-Waxman cases, the asserted portfolio commonly includes:
- Listed composition-of-matter patents
- Method-of-use patents tied to labeling
- Formulation or polymorph patents (for fixed-dose combinations or specific salt/solid forms)
- Manufacturing process patents (less common as “listed” but sometimes asserted)
No asserted patent list is provided, so infringement and validity analysis cannot be tied to actual claim numbers or statutory bases.
How does Azurity’s Paragraph IV certification factor into 1:26-cv-00265?
Answer: Not specified.
Typical Paragraph IV case mechanics
When a generic applicant files an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, the NDA holder can sue within statutory windows. But without:
- the ANDA number,
- the reference listed drug (RLD),
- the certification type (IV vs I/II/III),
- or the specific listed patents,
no accurate linkage can be made between the certification and the claims asserted in this docket.
What is the procedural posture of Aurobindo v. Azurity (1:26-cv-00265): complaint, TRO, motions, claim construction, trial?
Answer: Not specified.
Litigation milestones to check in a typical district court docket
A full litigation posture report normally includes:
- complaint filing date and first answer date
- amended complaints
- early motions (dismissal, transfer, enforceability challenges)
- Markman schedule and claim construction orders
- summary judgment
- preliminary injunction/TRO activity if sought
- trial scheduling or settlement docket events
No docket events were provided.
Which claims and infringement theories are at issue in Aurobindo v. Azurity?
Answer: Not specified.
Infringement and noninfringement arguments typically used in Hatch-Waxman
A defensible analysis requires actual claim language and at least one of:
- ANDA product label allegations
- proposed generic composition or process
- bioequivalence approach or formulation details
- noninfringement and invalidity expert positions
None are provided.
How strong is Aurobindo’s patent estate in this dispute?
Answer: Cannot be evaluated from the provided information.
What “strength” analysis requires
A litigation-ready strength score normally integrates:
- remaining patent term
- prosecution history estoppel and claim scope
- whether the asserted patents have prior litigation outcomes
- obviousness anticipation risk based on the specific prior art set
- enforceability factors (inequitable conduct allegations, patent eligibility)
No asserted patents are identified, so no strength analysis can be made.
What invalidity arguments are likely being raised by Azurity in 1:26-cv-00265?
Answer: Not specified.
Common invalidity grounds in this drug context
Typical defenses include:
- lack of novelty under 35 U.S.C. § 102
- obviousness under 35 U.S.C. § 103
- indefiniteness under 35 U.S.C. § 112
- written description/enablement issues
- patent-ineligible subject matter under § 101 (for method claims)
- prosecution history-based scope narrowing
But without asserted claim sets, the analysis cannot be anchored to real legal targets.
Is there an FDA regulatory or Orange Book linkage for the asserted product?
Answer: Not specified.
Why Orange Book status drives launch and damages models
For Hatch-Waxman:
- the identity of the RLD
- the listed patents (and their expiration)
- and whether the case is tied to market exclusivity, listed patents, or both
drive:
- expected design-around space
- likelihood of 30-month stay
- settlement and noninfringement/invalidity negotiation leverage
- generic launch timing and damages exposure
No Orange Book listing details are provided.
Has this case led to settlement, consent judgment, or stipulations?
Answer: Not specified.
What settlement terms would change for business planning
If a settlement exists, it usually allocates:
- launch date carve-outs
- stipulated noninfringement or license scope
- payment structure (if any)
- ongoing marketing injunctions or carve-outs for dosage forms/strengths
- dismissal with or without prejudice
No settlement information is included.
Does 1:26-cv-00265 involve a biosimilar or biologic pathway?
Answer: Not specified.
Why biosimilar context changes the litigation framework
Biosimilar patent cases use different statutory frameworks and may involve:
- BPCIA “patent dance”
- arbitration under 42 U.S.C. § 262(l)
- different stay and timing mechanics
The drug class is not provided, so biosimilar vs ANDA frameworks cannot be determined.
Practical launch-risk analysis for Aurobindo and Azurity from this docket
Answer: Not possible without asserted drug/patents, exclusivity status, and procedural timeline.
What a launch-risk model needs
A launch-risk model depends on:
- asserted patent expiration dates
- court schedule and likelihood of injunction outcomes
- whether the patents are listed for the exact dosage form/strength
- any design-around path (salt form, polymorph, formulation)
- whether the court has issued claim constructions that narrow scope
None of these inputs are provided.
Key Takeaways
- Case identifier is provided (1:26-cv-00265), but the asserted drug, Orange Book listing, patents, and docket events are not.
- A litigation summary tied to specific patents and claims cannot be produced without inventing facts.
- Business risk analysis (exclusivity, launch timing, damages exposure, and design-around feasibility) is not computable from the provided input.
FAQs
- What does a “1:26-cv-00265” docket number typically indicate in US patent litigation timing?
- How do Orange Book-listed patents drive the 30-month stay in ANDA Paragraph IV cases?
- What claim types (composition, method-of-use, formulation) most commonly drive Hatch-Waxman infringement outcomes?
- What evidence most often supports noninfringement in formulation or polymorph disputes?
- How does settlement in Hatch-Waxman usually affect authorized generic launch and market exclusivity?
References
- Public docket sources were not provided in the input; no specific court filings or patent documents can be cited.
